Abstract
Objective To compare the population rate of COVID-19 and influenza hospitalizations by age, COVID-19 vaccine status and pandemic phase.
Design Observational retrospective study
Setting Residents of British Columbia (population 5.3 million), Canada
Participants Hospitalized patients due to COVID-19 or historical influenza
Main outcome measures This population based study in a setting with universal healthcare coverage, used COVID-19 case and hospital data for COVID-19 and influenza. Admissions were selected from March 2020 to February 2021 for the annual cohort and the first 8 weeks of 2022 for the peak cohort of COVID-19 (Omicron era). Influenza annual and peak cohorts were from three years with varying severity: 2009/10, 2015/16, and 2016/17. We estimated hospitalization rates per 100,000 population by age group.
Results Similar to COVID-19 with median age 66 (Q1-Q3 44-80), influenza 2016/17 mostly affected older adults, with median age 78 (64-87). COVID-19 and influenza 2016/17 hospitalization rate by age group were “J” shaped. The rates for mostly unvaccinated COVID-19 patients in 2020/21 in the context of public health restrictions were significantly higher than influenza among individuals 30 to 69 years of age, and comparable to a severe influenza year (2016/17) among 70+. In early 2022 (Omicron peak), rates primarily due to COVID-19 among vaccinated adults were comparable with influenza 2016/17 in all age groups while rates among unvaccinated COVID-19 patients were still higher than influenza among 18+. In the pediatric population, COVID-19 hospitalization rates were similar to or lower than influenza.
Conclusions Our paper highlighted the greater population-level impact of COVID-19 compared with influenza in terms of adult hospitalizations, especially among those unvaccinated. However, influenza had greater impact than COVID-19 among <18 regardless of vaccine status or the circulating variant.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The BCC19C was established and is maintained through operational support from Data Analytics, Reporting and Evaluation (DARE), and BC Centre for Disease Control (BCCDC) at the Provincial Health Services Authority.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work was performed under BCCDC mandate to perform population health surveillance and falls under the Behavioral Research Ethics Board at the University of British Columbia (approval # H20-02097).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The DAD and COVID-19 databases were made available through British Columbia COVID-19 Cohort (BCC19C), a public health surveillance platform integrating COVID-19 datasets (testing, cases, hospitalizations, vaccinations) with administrative data holdings for the BC population (e.g., medical visits, hospitalizations, emergency room visits, prescription drugs, chronic conditions, vital statistics). We are not permitted to share these data. BCC19C data are only available to researchers who request and meet the criteria for access.
